share_log

Hypera (OTCMKTS:HYPMY) Stock Passes Above Fifty Day Moving Average of $7.58

Financial News Live ·  Aug 7, 2022 01:02

Hypera S.A. (OTCMKTS:HYPMY – Get Rating) crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $7.58 and traded as high as $8.14. Hypera shares last traded at $8.12, with a volume of 2,876 shares traded.

Hypera Price Performance

The company has a market cap of $5.23 billion, a PE ratio of 19.33 and a beta of 0.82. The company has a fifty day moving average price of $7.58 and a 200 day moving average price of $7.25.

About Hypera

(Get Rating)

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.

Featured Articles

  • Get a free copy of the StockNews.com research report on Hypera (HYPMY)
  • MarketBeat: Week in Review 8/1 – 8/5
  • How to Use High Beta Stocks to Maximize Your Investing Profits
  • Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
  • Why Apple Could Be At All-Time Highs By Year End
  • Beyond Meat Is Not Beyond Hope, And It's Cheap

Receive News & Ratings for Hypera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypera and related companies with MarketBeat.com's FREE daily email newsletter.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment